Login to Your Account


$150M up front, back end $3B-plus

Vice President of Research Michael Holmes said Sangamo Therapeutics Inc.'s potential $3 billion-plus deal with Gilead Sciences Inc.'s Kite Pharma unit "leaves open a variety of areas for us to move into," with details to come later.

more »


Our Habitat for All Things Science
GWAS in Chinese population implicates immune system in Alzheimer's disease

A study has identified common genetic variants in the Chinese population contributing to the risk of developing Alzheimer's disease (AD) that possibly exert functional effects through the immune system, which could have important implications for AD management.

The search continues for promising biomarkers and effective disease-modifying therapies for AD. The current drug development approaches mainly target the disease's hallmark pathology of amyloid-beta (Abeta) protein accumulation in the brain leading to Abeta plaque deposition.

READ MORE »

Opinion


Partners in Focus